Combination lipid therapy in type 2 diabetes

New England Journal of Medicine

Volumn 363, Issue 7, 2010, Pages 694-

  Perkins Jr , William J ^a  

^a WAKE FOREST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); DIET RESTRICTION; DRUG EFFECT; DRUG TREATMENT FAILURE; HAZARD RATIO; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LETTER; LIPID ANALYSIS; PRIORITY JOURNAL; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASE; DRUG COMBINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERTRIGLYCERIDEMIA; PROCETOFEN; SIMVASTATIN; TRIGLYCERIDES;

EID: 77956645718     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1006407     Document Type: Letter

References (2)

1. Emerging Risk Factors Collaboration. Major lipids, apolipo-proteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
2. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VAHIT). Arch Intern Med 2002;162:2597-604.